comparemela.com

Latest Breaking News On - Athira pharma - Page 7 : comparemela.com

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024 Plans to.

United statesMark littonHans moebiusJulie rathbunAthira pharmaSecurities exchangeMotor neurone disease associationExchange commissionAlzheimer association international congressAthira pharma incAmyotrophic lateral sclerosis consortiumAmerican association of neurologyManagement teamChief executive officerChief medical officerSenior scientific advisor

Athira Pharma, Inc Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer s Disease

Athira Pharma, Inc. announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer s disease. Fosgonimeton is a.

Athira pharma incAthira pharmaGlobal statistical test

Athira Pharma, Inc : Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer s Disease

Athira Pharma, Inc : Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer s Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJulie rathbunMark littonAthira pharmaSecurities exchangeAthira pharma incExchange commissionChief executive officerGlobal statistical testSecurities actSecurities exchange actPrivate securities litigation reform actMedia contact

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer s Disease Seite 1

03.01.2024 - Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach . Seite 1

Mark littonAthira pharma incAthira pharmaChief executive officerAthira pharma chartThira pharma kursThira pharma aktie

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer s Disease -January 03, 2024 at 07:02 am EST

Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of.

United statesJulie rathbunMark littonAthira pharmaSecurities exchangeAthira pharma incExchange commissionChief executive officerGlobal statistical testSecurities actSecurities exchange actPrivate securities litigation reform actMedia contact

vimarsana © 2020. All Rights Reserved.